ClinicalTrials.gg
CompletedNCT00139659Updated Jun 2, 2010Results posted

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma

A Phase 3 interventional study of Inhaled Insulin and Subcutaneous Insulin in Asthma and Diabetes Mellitus, sponsored by Pfizer. Completed at 102 sites in 5 countries. Open to participants aged 18 Years to 77 Years. Per ClinicalTrials.gov, last updated 2010-06-02.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
18 Years to 77 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Asthma by Pfizer — 4 open to participants now, 4 under way, 2 of them phase 3. Asthma · Pfizer.

Enrollment
3rd of 20
288 · median 48
Started
2003
the only one that year
Phase 3
3 of 24
2 open now
Registered
1st of 24
by date

Among the 24 studies in Asthma by Pfizer, this one is the 3rd largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2003, is one of 3 in phase 3, and was the 1st registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

4 of the 24 studies in Asthma by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 77 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Asthma by Pfizer, or all of them as a file.
02

Study summary

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Asthma

03

Conditions studied

  • Asthma
  • Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 77 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diabetes Mellitus (Type 1 or Type 2) currently controlled with injected insulin
  • Mild intermittent or mild to moderate persistent asthma

Exclusion criteria

Exclusion Criteria:

  • Poorly controlled, unstable or -dependent asthma, insulin pump therapy, smoking
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
288 participants (actual)

Study arms

  • Experimental
    Inhaled Insulin

    Drug: Inhaled Insulin

  • Active comparator
    Subcutaneous Insulin

    Drug: Subcutaneous Insulin

Interventions

  • Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.

  • Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Change for Forced Expiratory Volume in 1 Second (FEV1)

    Annualized rates of change (slope throughout time from baseline to end of study\[visit\]) for forced expiratory volume in 1 second (FEV1) (liters per year \[L/yr\]) measured 30 minutes following the administration of albuterol.

    Time frame: Weeks -3, -2, -1, 1, 2, 3, 4, 6, 12, 18, 26, 39, and 52

  2. Annualized Rate of Change for Hemoglobin-adjusted Carbon Monoxide Diffusion Capacity (DLco)

    Annualized rates of change (slope throughout time from baseline to end of study\[visit\]) for hemoglobin-adjusted carbon monoxide diffusion capacity (DLco)in milliliters per minute/millimeters of mercury/year (ml/min/mmHg/yr) measured 30 minutes following the administration of albuterol.

    Time frame: Weeks -3, -2, -1, 1, 2, 3, 4, 6, 12, 18, 26, 39, and 52

  3. Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second (FEV1)

    Change from Baseline at each visit in post-bronchodilator forced expiratory volume in one second (FEV1). FEV1 was measured in liters (L) 30 minutes following the administration of albuterol. Change from baseline: mean FEV1 (L) at observation minus baseline value.

    Time frame: Baseline through Week 52 Last Observation Carried Forward (LOCF)

  4. Change From Baseline in Post-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco)

    Carbon Monoxide Diffusing Capacity (DLco) measured in milliters/minutes/millimeters of mercury (mL/min/mmHg) 30 minutes following the administration of albuterol. Change from Baseline: mean DLco (mL/min/mmHg) at observation minus baseline value.

    Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)

Secondary outcomes

  1. Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1)

    Change from Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) at each visit. FEV1 was measured in liters (L) before the administration of albuterol. Change from baseline: mean FEV1 (L) at observation minus mean baseline value.

    Time frame: Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)

  2. Change From Baseline in Pre-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco)

    Change From Baseline in Pre-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco) measured in milliters/minutes/millimeters of mercury (mL/min/mmHg): change = DLco at observation minus DLco at Baseline.

    Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation carried Forward (LOCF)

  3. Change From Baseline in Pre-Insulin Forced Expiratory Volume in One Second (FEV1)

    Change from Baseline in Pre-Insulin Forced Expiratory Volume in one second (FEV1) measured in liters (L): change = FEV1 at observation minus FEV1 at Baseline.

    Time frame: Baseline, Week 9, Week 51, Week 51 Last Observation Carried Forward

  4. Change From Baseline in Pre-Insulin Carbon Monoxide Diffusing Capacity (DLco)

    Change From Baseline in Pre-Insulin Carbon Monoxide Diffusing Capacity (DLco) measured in milliters/minutes/millimeters of mercury (mL/min/mmHg): change = DLco at observation minus DLco at Baseline.

    Time frame: Baseline, Week 9, Week 51, Week 51 Last Observation Carried Forward (LOCF)

  5. Change From Baseline in Post-bronchodilator Forced Vital Capacity (FVC)

    Change from baseline in Post-bronchodilator Forced Vital Capacity (FVC) measured in liters (L) 30 minutes following the administration of albuterol: change = FVC at observation minus FVC at Baseline.

    Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)

  6. Bronchodilator Responsiveness as Determined by the Change in Forced Expiratory Volume in 1 Second (FEV1) Pre-albuterol and 30 Minutes Post-albuterol

    Responsiveness was the percent change from the forced expiratory volume in 1 second (FEV1) value before bronchodilator use to the FEV1 value 30 minutes after bronchodilator use, operationally defined as \[(post-bronchodilator FEV1 minus pre-bronchodilator FEV1 divided by pre-bronchodilator FEV1\] multiplied by 100.

    Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52

  7. Percent Predicted and Percent Change From Baseline in Post-Bronchdilator Forced Expiratory Volume in One Second (FEV1)

    Percent predicted change from Baseline in post-bronchodilator forced expiratory volume in one second (FEV1) measured in liters (L): National Health and Nutrition Examination Survey (NHANES III) reference standard. Percent change from Baseline in post-bronchdilator FEV1 measured in liters (L): (observed value minus Baseline value) divided by Baseline value \*100%.

    Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)

  8. Change From Baseline in Insulin Dose Responsiveness for Forced Expiratory Volume in One Second (FEV1) Measured 10 and 60 Minutes After the First Daily Dose of Insulin

    Change from Baseline in Insulin Dose Responsiveness for Forced Expiratory Volume in one second (FEV1) measured 10 and 60 minutes after the first daily dose of insulin. Insulin dose responsiveness = the difference between FEV1 value following a dose of insulin and FEV1 value before a dose of insulin, operationally defined as the post dose FEV1 value minus predose FEV1 value.

    Time frame: Baseline, Week 9, Week 51

  9. Percent Predicted and Percent Change From Baseline in 10 Minute and 60 Minute Post-Insulin Forced Expiratory Volume in One Second (FEV1)

    Percent predicted change from Baseline in 10 Minute and 60 Minute post-insulin forced expiratory volume in one second (FEV1) measured in liters (L): National Health and Nutrition Examination Survey (NHANES III) reference standard. Percent change from Baseline in FEV1 measured in liters (L) 10 and 60 Minutes post-insulin. Percent change = (value at observation minus Baseline value) divided by Baseline value \*100%.

    Time frame: Baseline, Week 9, Week 51, Week 51 Last Observation Carried Forward (LOCF)

  10. Change From Baseline in Insulin Dose Responsiveness for Carbon Monoxide Diffusing Capacity (DLco) Measured 10 and 60 Minutes After the First Daily Dose of Insulin

    Carbon Monoxide Diffusing Capacity (DLco) dose responsivness 10 and 60 minutes after insulin. DLco dose-responsiveness to insulin was defined as the difference between the DLco value following a dose of insulin and DLco value before a dose of insulin, operationally defined as the post-dose DLco value minus pre-dose DLco value.

    Time frame: Baseline, Week 9, Week 51

  11. Methacholine Challenge

    Methacholine Challange: performed on a subset of subjects using the 5-breath dosimeter method. Subjects were challenged with ascending doses of nebulized methacholine; dosing schedule: 0.03, 0.06, 0.12, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16.0, 32.0 milligrams per milliliter (mg/ml) administered in 5-minute intervals. Forced expiratory volume in 1 second (FEV1) was measured 1-3 minutes after each inhalation of methacholine solution. Testing continued until highest FEV1 decreased by ≥20% from the challenge (post-diluent) reference, or until completion all doses.

    Time frame: 1 to 2 days following Weeks -3 and -1 visits, and at Week 11, Week 50, and Week 52 (+5)

  12. Mean Weekly Morning and Evening Peak Expiratory Flow Rate (PEFR) and Forced Expiratory Volume in 1 Second (FEV1)

    Subjects measured peak expiratory flow rate (PEFR) and forced expiratory volume in 1 second (FEV1) twice daily and entered the results in an electronic diary. Daily data were used to calculate the mean PEFR and FEV1 for each week (observed weekly mean and change from baseline in weekly mean). For each subject, the mean weekly morning (and evening) PEFR and FEV1 was defined as the sum of the daily morning (and evening) PEFR (and FEV1) measurements during the week divided by the number of non-missing PEFR (and FEV1) measurements during the week.

    Time frame: Week -3 through Week 52

  13. Mean Weekly Number of Puffs of Albuterol Used (Rescue Medication)

    All subjects used an electronic symptom diary to record their daily use of short-acting bronchodilators. Subjects recorded the sum of their short-acting bronchodilator use (puffs of albuterol) daily, immediately upon arising, and again in the evening or before bed.

    Time frame: Daily: Baseline to end of study

  14. Number of Subjects With Step-up and Step-down Changes in Classification of Asthma Severity by Medication Usage

    All asthma medication changes during the study were classified as step-up or step-down according to treatment guidelines. Step 1: Intermittant Asthma; Step 2: Mild Persistent Asthma; Step 3: Moderate Persistent Asthma; Step 4: Severe Persistent Asthma. The number of subjects in each step classification of asthma severity were provided at each assessment timepoint for each treatment group, with a shift table indicating the number of subjects moving from each step classification at each timepoint.

    Time frame: Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52, Week 54, Week 58

  15. Step Classification of Asthma Severity by Medication Usage

    Step classification of asthma severity by medication usage. Subjects were classified at each visit according to the medication used on the day of the particular time-point; Step 1: intermittent asthma, Step 2: mild persistent asthma, Step 3: moderate persistent asthma, Step 4: severe persistent asthma. The number (%) of subjects in each step classification were provided at each assessment timepoint with a shift table indicating the number (%) of subjects moving from each step classification at each time-point.

    Time frame: Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52, Week 54, Week 58

  16. Mean Weekly Asthma Symptom Scores

    Mean weekly asthma symptom scores: subjects recorded their asthma symptom scores in an electronic symptom diary twice daily throughout the study, immediately upon awakening (5-10 AM) and in the evening or at bedtime (7-12 PM). Questions included extent of albuterol use, symptoms of wheezing, coughing, activity limitations and sleep; scale 0 (none/fine) to 3 (severe/ continuous/bad night).

    Time frame: Baseline through end of study

  17. Incidence of Non-severe Asthma Exacerbations

    Non-severe asthma exacerbation = one of the following: any home monitored morning (4:45 am - 10:15 am) forced expiratory volume in 1 second (FEV1) \<80% of the morning baseline for 2 or more consecutive days; or home monitored FEV1 \<60% of Baseline at any time. Percent of Baseline = 100\*(daily FEV1)/Baseline weekly FEV1. Subject-months=elapsed number of months a subject was in the study in each time interval. Crude event rate = total events divided by subject-months.

    Time frame: 0 to 1 week to > 12 months

  18. Incidence of Severe Asthma Exacerbations

    Severe asthma exacerbation was defined as one of the following: subject received oral (systemic) corticosteriods for the treatment of asthma; or subject had an unscheduled visit to a physician, emergency room, or hospital for the treatment of asthma. Subject-months=elapsed number of months a subject was in the study in each time interval. Crude event rate = total events divided by subject-months \* 100.

    Time frame: 0 to 1 Week to > 12 Months

  19. Number of Systemic Corticosteroid Rescues

    Number of subjects who used a systemic corticosteroid at any time during the study, and the total number of systemic corticosteroid rescues. New rescue event = \>=2 consecutive days between the end of one event and the start of another event.

    Time frame: Baseline through Week 52

  20. Asthma Control as Measured by the Asthma Control Questionnaire©

    Asthma Control Questionnaire©: 6 self-administered questions that assess asthma control over the past week covering nocturnal waking, morning symptoms, activity limitations, shortness of breath, wheezing, and short-acting bronchodilator use; 7-point ordinal rating scale from 0 (good control) to 6 (poor control). A seventh question was completed by a health professional on forced expiratory volume in 1 second (FEV1) % predicted using a one-week recall period; scale: 0 (\>95% predicted) to 6 (\<50% predicted). Overall score = mean of questions 1 - 7.

    Time frame: Baseline, Weeks 4, 12, 26, 39, 52

  21. Baseline Dyspnea Index (BDI)

    Total score = the sum of the numeric grades from the three dyspnea index questions. Functional Impairment rating scale: Grade 4 (no impairment) to Grade 0 (very severe impairment); Magnitude of Task rating scale: Grade 4 (extraordinary) to Grade 0 (no task); and Magnitude of Effort rating scale: Grade 4 (extraordinary) to grade 0 (no effort).

    Time frame: run-in period

  22. Transition Dyspnea Index (TDI): Change in Total Score

    Transition Dyspnea Index total score = sum of the numeric grades from the three dyspnea index questions: Change in Functional Impairment, Change in Magnitude of Task, and Change in Magnitude of Effort. Rating scale: -3 (major deterioration), -2 (moderate deterioration), -1 (minor deterioration, 0 (no change), +1 (minor improvement), +2 (moderate improvement), +3 (major improvement).

    Time frame: Week 4, Week 12, Week 26, Week 39, Week 52

  23. Glycosylated Hemoglobin (HbA1c)

    Glycosylated Hemoglobin (HbA1c): observed mean values at Baseline and each observation, and change from Baseline. Change from Baseline = mean HbA1c at observation minus mean HbA1c at Baseline.

    Time frame: Baseline, Week 6, Week 12, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)

  24. Fasting Plasma Glucose

    Fasting plasma glucose (milligrams per deciliter \[mg/dL\]) at Baseline, and change from Baseline. Change from baseline: mean of value of fasting plasma glucose in mg/dL at observation minus baseline value.

    Time frame: Baseline, Week 6, Week 12, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)

  25. Body Weight: Mean Baseline and Change From Baseline

    Body weight: mean Baseline and change from Baseline in kilograms (kg). Change from baseline = mean body weight in kilograms (kg) at observation minus baseline value.

    Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 11, Week 12, Week 18, Wek 26, Week 39, Week 50, Week 51, Week 52, Week 52 Last Observation Carried Forward (LOCF)

  26. Total Daily Long-Acting Insulin Dose (Unadjusted for Body Weight)

    Total Daily Long-Acting Insulin Dose Unadjusted for Body Weight: long-acting insulin included Insulin NPH, Ultralente, and Insulin Glargine for both groups. Inhaled Insulin reported in mg. Subcutaneous Insulin reported in units.

    Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52

  27. Total Daily Long-Acting Insulin Dose Adjusted for Body Weight

    Total daily dose of long-acting insulin adjusted for body weight (units per kilogram \[kg\]). Long-acting insulin included Insulin NPH, Ultralente, and Insulin Glargine for both groups. Inhaled Insulin reported in mg/kg. Subcutaneous Insulin reported in units/kg.

    Time frame: Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52

  28. Total Daily Short-Acting Insulin Dose (Unadjusted for Body Weight)

    Average Total Daily Insulin Dose: short-acting insulin (milligrams \[mg\]). Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.

    Time frame: Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52

  29. Total Daily Short-Acting Insulin Dose Adjusted for Body Weight

    Total Daily Short-Acting Insulin Dose adjusted for body weight (units divided by kg). Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.

    Time frame: Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52

  30. Lipids: Median Change From Baseline to Last Observation

    Lipids: median changes (milligrams per deciliter \[mg/dL\]) from Baseline median to last observation in cholesterol (random), triglycerides (random), high density lipoprotein (HDL) cholesterol and low density lipoprotein (LDL) cholesterol. Normalized data was used in the computations. Last observation = last observation while on study drug or during the lag. Measures of dispersion for median changes in lipids were not determined.

    Time frame: Baseline to Last Observation

  31. Hypoglycemic Event Rates

    A Hypoglycemic event was identified by characteristic symptoms of hypoglycemia with no blood glucose check with prompt resolution with food intake, subcutaneous glucagon, or intravenouus glucose; characteristic symptoms with blood glucose of 59 milligrams per deciliter (mg/dL) (3.2 mmol/L) or less with blood glucose check; or any glucose measurement of 49 mg/dL (2.7 mmol/L) or less, with or without symptoms. Crude event rate = total events divided by subject months. Subject months = elapsed number of months a subject was in the study in each time interval.

    Time frame: 0 to 1 month to 11 to 12 months, and Overall

  32. Severe Hypoglycemic Event Rates

    Severe hypoglycemic event = all 3 of the following criteria were met: subject unable to treat self, exhbited at least 1 neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, loss of consciousness); blood glucose measurement was ≤ 49 mg/dL, or not measured but clinical manifestations reversed by oral carbohydrates, subcutaneous glucagon, or i.v. glucose. Crude event rate = number of events divided by 100 subject-months. Subject months = elapsed number of months subject was in study in each time interval.

    Time frame: 0 to 1 month to 11 to 12 months, and Overall

07

Results

Posted May 12, 2010
Limitations and caveats
Data for some secondary endpoints were not tabulated or analyzed for this study and some concomitant medication data were not accurately recorded and tabulated due to lack of resources resulting from scaling down of Exubera® development.

Participant flow

Subjects were recruited at 63 centers and participated in the study between 10 January 2003 and 22 October 2008.

Participant flow — Overall Study
MilestoneInhaled InsulinSubcutaneous Insulin
Started146141
Completed106123
Not completed4018
Withdrew: Adverse event121
Withdrew: Lack of efficacy11
Withdrew: Lost to follow-up73
Withdrew: Reason not specified63
Withdrew: Withdrawal by subject1410

Outcome measures

PrimaryAnnualized Rate of Change for Forced Expiratory Volume in 1 Second (FEV1)

Annualized rates of change (slope throughout time from baseline to end of study\[visit\]) for forced expiratory volume in 1 second (FEV1) (liters per year \[L/yr\]) measured 30 minutes following the administration of albuterol.

Time frame:
Weeks -3, -2, -1, 1, 2, 3, 4, 6, 12, 18, 26, 39, and 52
Reported as:
Mean · L/yr
Annualized Rate of Change for Forced Expiratory Volume in 1 Second (FEV1)
L/yrInhaled InsulinSubcutaneous Insulin
Annualized Rate of Change for Forced Expiratory Volume in 1 Second (FEV1)-0.070 ± 0.020-0.035 ± 0.019
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · longitudinal data analysis model · Mean difference (final values): -0.034 · 90% CI -0.080 to 0.011Primary analysis model includes terms of Treatment, Time, Baseline Pulmonary Function Test (PFT), Center, Age, Sex, Baseline Height, Type of Diabetes, and Controller Medications Use on day of randomization.
SecondaryChange From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1)

Change from Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) at each visit. FEV1 was measured in liters (L) before the administration of albuterol. Change from baseline: mean FEV1 (L) at observation minus mean baseline value.

Time frame:
Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Reported as:
Mean · liters
Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1)
litersInhaled InsulinSubcutaneous Insulin
Baseline (141, 139)2.435 ± 0.7482.412 ± 0.727
Week 1 (123, 125)-0.057 ± 0.142-0.035 ± 0.131
Week 2 (n=127, 117)-0.065 ± 0.159-0.034 ± 0.150
Week 3 (n=130, 121)-0.067 ± 0.185-0.044 ± 0.171
Week 4 (n=123, 130)-0.076 ± 0.185-0.037 ± 0.181
Week 6 (n=130, 135)-0.059 ± 0.211-0.034 ± 0.170
Week 12 (n=125, 130)-0.067 ± 0.237-0.032 ± 0.193
Week 18 (n=125, 125)-0.063 ± 0.218-0.042 ± 0.183
Week 26 (n=120, 129)-0.058 ± 0.190-0.043 ± 0.195
Week 39 (n=108, 124)-0.076 ± 0.195-0.044 ± 0.186
Week 52 (n=106, 112)-0.136 ± 0.259-0.056 ± 0.230
Week 52 LOCF (n=141, 139)-0.119 ± 0.259-0.058 ± 0.222
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.025 · 90% CI -0.065 to 0.015
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.034 · 90% CI -0.073 to 0.006
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.024 · 90% CI -0.063 to 0.016
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.035 · 90% CI -0.075 to 0.004
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.027 · 90% CI -0.067 to 0.012
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.033 · 90% CI -0.073 to 0.008
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.018 · 90% CI -0.059 to 0.023
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.010 · 90% CI -0.052 to 0.031
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.025 · 90% CI -0.068 to 0.017
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.073 · 90% CI -0.117 to -0.029
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.061 · 90% CI -0.108 to -0.015
SecondaryChange From Baseline in Pre-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco)

Change From Baseline in Pre-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco) measured in milliters/minutes/millimeters of mercury (mL/min/mmHg): change = DLco at observation minus DLco at Baseline.

Time frame:
Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation carried Forward (LOCF)
Reported as:
Mean · ml/min/mmHg
Change From Baseline in Pre-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco)
ml/min/mmHgInhaled InsulinSubcutaneous Insulin
Baseline (n=141, 139)23.034 ± 5.92122.911 ± 6.059
Week 1 (n=123, 125)-0.749 ± 1.467-0.452 ± 1.220
Week 2 (n=126, 114)-0.835 ± 1.353-0.456 ± 1.485
Week 3 (n=128, 119)-0.855 ± 1.407-0.556 ± 1.452
Week 4 (n=122, 127)-1.120 ± 1.609-0.648 ± 1.500
Week 6 (n=129, 135)-1.169 ± 1.583-0.669 ± 1.441
Week 12 (n=124, 128)-1.018 ± 1.842-0.725 ± 1.788
Week 18 (n=123, 125)-0.906 ± 1.756-0.646 ± 1.748
Week 26 (n=117, 127)-0.945 ± 1.683-0.561 ± 1.982
Week 39 (n=106, 125)-0.821 ± 1.742-0.550 ± 1.805
Week 52 (n=105, 111)-1.699 ± 2.157-0.911 ± 2.239
Week 52 LOCF (n=141, 139)-1.557 ± 2.109-0.785 ± 2.141
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.327 · 90% CI -0.679 to 0.026
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.378 · 90% CI -0.729 to -0.027
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.346 · 90% CI -0.696 to 0.004
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.496 · 90% CI -0.847 to -0.145
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.610 · 90% CI -0.960 to -0.260
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.360 · 90% CI -0.721 to 0.001
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.291 · 90% CI -0.655 to 0.073
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.420 · 90% CI -0.788 to -0.052
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.337 · 90% CI -0.717 to 0.042
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.789 · 90% CI -1.181 to -0.397
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.786 · 90% CI -1.178 to -0.393
SecondaryChange From Baseline in Pre-Insulin Forced Expiratory Volume in One Second (FEV1)

Change from Baseline in Pre-Insulin Forced Expiratory Volume in one second (FEV1) measured in liters (L): change = FEV1 at observation minus FEV1 at Baseline.

Time frame:
Baseline, Week 9, Week 51, Week 51 Last Observation Carried Forward
Reported as:
Mean · liters
Change From Baseline in Pre-Insulin Forced Expiratory Volume in One Second (FEV1)
litersInhaled InsulinSubcutaneous Insulin
Baseline (n=130, 133)2.449 ± 0.7752.403 ± 0.727
Week 9 (n=111, 108)-0.038 ± 0.235-0.028 ± 0.163
Week 51 (n=103, 119)-0.078 ± 0.227-0.017 ± 0.245
Week 51 LOCF (n=130, 133)-0.068 ± 0.237-0.018 ± 0.237
SecondaryChange From Baseline in Pre-Insulin Carbon Monoxide Diffusing Capacity (DLco)

Change From Baseline in Pre-Insulin Carbon Monoxide Diffusing Capacity (DLco) measured in milliters/minutes/millimeters of mercury (mL/min/mmHg): change = DLco at observation minus DLco at Baseline.

Time frame:
Baseline, Week 9, Week 51, Week 51 Last Observation Carried Forward (LOCF)
Reported as:
Mean · ml/min/mmHg
Change From Baseline in Pre-Insulin Carbon Monoxide Diffusing Capacity (DLco)
ml/min/mmHgInhaled InsulinSubcutaneous Insulin
Baseline (n=128, 131)22.836 ± 6.08722.718 ± 6.128
Week 9 (n=109, 106)-1.130 ± 1.663-0.663 ± 1.549
Week 51 (n=102, 116)-1.156 ± 1.825-0.630 ± 2.023
Week 51 LOCF (n=128, 131)-1.185 ± 1.804-0.533 ± 1.990
SecondaryChange From Baseline in Post-bronchodilator Forced Vital Capacity (FVC)

Change from baseline in Post-bronchodilator Forced Vital Capacity (FVC) measured in liters (L) 30 minutes following the administration of albuterol: change = FVC at observation minus FVC at Baseline.

Time frame:
Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Reported as:
Mean · liters
Change From Baseline in Post-bronchodilator Forced Vital Capacity (FVC)
litersInhaled InsulinSubcutaneous Insulin
Baseline (n=141, 139)3.355 ± 0.9633.341 ± 0.918
Week 1 (n=123, 125)-0.068 ± 0.181-0.046 ± 0.134
Week 2 (n=126, 115)-0.057 ± 0.190-0.053 ± 0.169
Week 3 (n=131, 119)-0.078 ± 0.205-0.068 ± 0.174
Week 4 (n=121, 129)-0.065 ± 0.193-0.051 ± 0.176
Week 6 (n=130, 135)-0.092 ± 0.287-0.043 ± 0.173
Week 12 (n=125, 129)-0.045 ± 0.222-0.056 ± 0.190
Week 18 (n=124, 125)-0.053 ± 0.225-0.069 ± 0.179
Week 26 (n=120, 128)-0.061 ± 0.215-0.052 ± 0.186
Week 39 (n=107, 124)-0.080 ± 0.209-0.057 ± 0.213
Week 52 (n=106, 112)-0.105 ± 0.288-0.088 ± 0.259
Week 52 LOCF (n=141, 139)-0.097 ± 0.278-0.083 ± 0.247
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.021 · 90% CI -0.066 to 0.023
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.000 · 90% CI -0.044 to 0.044
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.012 · 90% CI -0.056 to 0.032
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.004 · 90% CI -0.048 to 0.041
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.045 · 90% CI -0.089 to -0.001
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): 0.010 · 90% CI -0.035 to 0.056
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): 0.018 · 90% CI -0.028 to 0.064
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.005 · 90% CI -0.051 to 0.041
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.022 · 90% CI -0.070 to 0.026
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.015 · 90% CI -0.064 to 0.034
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.015 · 90% CI -0.067 to 0.037
SecondaryBronchodilator Responsiveness as Determined by the Change in Forced Expiratory Volume in 1 Second (FEV1) Pre-albuterol and 30 Minutes Post-albuterol

Responsiveness was the percent change from the forced expiratory volume in 1 second (FEV1) value before bronchodilator use to the FEV1 value 30 minutes after bronchodilator use, operationally defined as \[(post-bronchodilator FEV1 minus pre-bronchodilator FEV1 divided by pre-bronchodilator FEV1\] multiplied by 100.

Time frame:
Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52
Reported as:
Mean · percent change in FEV1
Bronchodilator Responsiveness as Determined by the Change in Forced Expiratory Volume in 1 Second (FEV1) Pre-albuterol and 30 Minutes Post-albuterol
percent change in FEV1Inhaled InsulinSubcutaneous Insulin
Baseline (n=141, 139)5.487 ± 5.1635.102 ± 6.416
Week 1 (n=123, 125)-0.015 ± 5.4520.347 ± 5.429
Week 2 (n=126, 115)0.683 ± 5.9840.347 ± 6.354
Week 3 (n=130, 119)-0.055 ± 6.0820.823 ± 5.449
Week 4 (n=121, 129)0.056 ± 6.3610.559 ± 5.733
Week 6 (n=130, 135)-0.460 ± 5.4800.504 ± 6.350
Week 12 (n=124, 129)0.721 ± 5.972-0.100 ± 6.783
Week 18 (n=124, 125)-0.095 ± 5.9090.154 ± 7.649
Week 26 (n=120, 128)-0.186 ± 5.6240.211 ± 5.080
Week 39 (n=107, 124)-0.283 ± 5.3680.133 ± 5.089
Week 52 (n=106, 112)0.640 ± 5.338-0.035 ± 6.156
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.632 · 90% CI -1.778 to 0.514
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): 0.020 · 90% CI -1.079 to 1.120
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): 0.582 · 90% CI -0.535 to 1.700
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.054 · 90% CI -1.184 to 1.077
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.535 · 90% CI -1.677 to 0.608
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.905 · 90% CI -2.014 to 0.203
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): 0.212 · 90% CI -0.899 to 1.323
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): 0.044 · 90% CI -1.080 to 1.169
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.240 · 90% CI -1.382 to 0.902
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.503 · 90% CI -1.673 to 0.668
SecondaryPercent Predicted and Percent Change From Baseline in Post-Bronchdilator Forced Expiratory Volume in One Second (FEV1)

Percent predicted change from Baseline in post-bronchodilator forced expiratory volume in one second (FEV1) measured in liters (L): National Health and Nutrition Examination Survey (NHANES III) reference standard. Percent change from Baseline in post-bronchdilator FEV1 measured in liters (L): (observed value minus Baseline value) divided by Baseline value \*100%.

Time frame:
Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Reported as:
Mean · percentage of FEV1
Percent Predicted and Percent Change From Baseline in Post-Bronchdilator Forced Expiratory Volume in One Second (FEV1)
percentage of FEV1Inhaled InsulinSubcutaneous Insulin
Baseline (n=141, 139)83.698 ± 14.09682.833 ± 15.219
Week 1: % of Predicted Value (n=123, 125)81.987 ± 14.44182.878 ± 15.438
Week 2: % of Predicted Value (n=126, 115)81.655 ± 13.98581.881 ± 15.017
Week 3: % of Predicted Value (n=131, 119)80.711 ± 13.85482.036 ± 15.354
Week 4: % of Predicted Value (n=121, 129)81.093 ± 15.14582.029 ± 14.914
Week 6: % of Predicted Value (n=130, 135)81.611 ± 14.55382.016 ± 15.509
Week 12: % of Predicted Value (n=125, 129)82.145 ± 13.88581.640 ± 14.673
Week 18: % of Predicted Value (n=124, 125)82.187 ± 14.40581.723 ± 14.505
Week 26: % of Predicted Value (n=120, 128)82.941 ± 14.29182.227 ± 14.305
Week 39: % of Predicted Value (n=107, 124)82.851 ± 14.44781.847 ± 14.794
Week 52: % of Predicted Value (n=106, 112)80.869 ± 14.93481.138 ± 14.461
Week 52 LOCF: % of Predicted Value (n=141, 139)80.136 ± 14.52880.687 ± 14.671
Week 1: % Change from Baseline (n=123, 125)-2.682 ± 5.780-1.238 ± 5.307
Week 2: % Change from Baseline (n=126, 115)-2.355 ± 5.909-1.142 ± 5.273
Week 3: % Change from Baseline (n=131, 119)-2.943 ± 7.583-1.057 ± 5.292
Week 4: % Change from Baseline (n=121, 129)-3.063 ± 6.926-0.833 ± 6.172
Week 6: % Change from Baseline (n=130, 135)-2.559 ± 8.725-0.957 ± 6.180
Week 12: % Change from Baseline (n=125, 129)-1.975 ± 8.495-1.226 ± 7.603
Week 18: % Change from Baseline (n=124, 125)-2.437 ± 8.713-1.247 ± 6.688
Week 26: % Change from Baseline (n=120, 128)-2.006 ± 6.891-1.189 ± 8.013
Week 39: % Change from Baseline (n=107, 124)-3.144 ± 7.507-1.466 ± 8.332
Week 52: % Change from Baseline (n=106, 112)-4.777 ± 8.794-2.002 ± 10.040
Week 52 LOCF: % Change from Baseline (n=141, 139)-4.129 ± 9.673-2.108 ± 9.652
SecondaryChange From Baseline in Insulin Dose Responsiveness for Forced Expiratory Volume in One Second (FEV1) Measured 10 and 60 Minutes After the First Daily Dose of Insulin

Change from Baseline in Insulin Dose Responsiveness for Forced Expiratory Volume in one second (FEV1) measured 10 and 60 minutes after the first daily dose of insulin. Insulin dose responsiveness = the difference between FEV1 value following a dose of insulin and FEV1 value before a dose of insulin, operationally defined as the post dose FEV1 value minus predose FEV1 value.

Time frame:
Baseline, Week 9, Week 51
Reported as:
Mean · liters
Change From Baseline in Insulin Dose Responsiveness for Forced Expiratory Volume in One Second (FEV1) Measured 10 and 60 Minutes After the First Daily Dose of Insulin
litersInhaled InsulinSubcutaneous Insulin
Baseline: 10 minutes (n=124, 131)-0.004 ± 0.0850.003 ± 0.086
Week 9: 10 minutes (n=105, 106)-0.008 ± 0.1300.005 ± 0.111
Week 51: 10 minutes (n=96, 113)0.000 ± 0.1130.013 ± 0.104
Baseline: 60 minutes (n=125, 131)-0.004 ± 0.1200.016 ± 0.130
Week 9: 60 minutes (n=105, 105)0.013 ± 0.1130.028 ± 0.137
Week 51: 60 minutes (n=99, 112)0.029 ± 0.1390.020 ± 0.123
SecondaryPercent Predicted and Percent Change From Baseline in 10 Minute and 60 Minute Post-Insulin Forced Expiratory Volume in One Second (FEV1)

Percent predicted change from Baseline in 10 Minute and 60 Minute post-insulin forced expiratory volume in one second (FEV1) measured in liters (L): National Health and Nutrition Examination Survey (NHANES III) reference standard. Percent change from Baseline in FEV1 measured in liters (L) 10 and 60 Minutes post-insulin. Percent change = (value at observation minus Baseline value) divided by Baseline value \*100%.

Time frame:
Baseline, Week 9, Week 51, Week 51 Last Observation Carried Forward (LOCF)
Reported as:
Mean · percent
Percent Predicted and Percent Change From Baseline in 10 Minute and 60 Minute Post-Insulin Forced Expiratory Volume in One Second (FEV1)
percentInhaled InsulinSubcutaneous Insulin
Baseline: 10 minutes (n=124, 131)94.402 ± 6.53294.391 ± 6.168
Week 9: 10 min.; % of Predicted Value (n=105, 106)92.698 ± 9.18794.190 ± 7.190
Week 9: 10 min;% Change from Baseline (n=105, 106)-1.864 ± 9.684-0.456 ± 8.638
Week 51: 10 min.;% of Predicted Value (n=96, 113)91.668 ± 8.22393.717 ± 9.305
Week 51:10 min;% Change from Baseline (n=96, 113)-2.760 ± 8.7890.228 ± 13.653
Week 51 LOCF:10 min;% Predicted Value (n=124, 131)91.196 ± 8.36693.882 ± 9.013
Week 51 LOCF:10 min;% Change from BL (n=124, 131)-3.176 ± 8.825-0.029 ± 12.946
Baseline: 60 minutes (n=125, 131)94.284 ± 6.54894.688 ± 5.260
Week 9: 60 min.; % of Predicted Value (n=105, 105)93.586 ± 8.21994.950 ± 7.526
Week 9: 60 min;% Change from Baseline (n=105, 105)-0.450 ± 9.464-0.031 ± 7.497
Week 51: 60 min.; % of Predicted Value (n=99, 112)92.302 ± 7.94994.084 ± 9.069
Week 51:60 min.;% Change from Baseline (n=99, 112)-1.699 ± 9.015-0.247 ± 10.349
Week 51 LOCF:60 min;% Predicted Value (n=125, 131)92.418 ± 8.54494.300 ± 8.823
Week 51 LOCF:60 min;% Change from BL (n=125, 131)-1.714 ± 9.512-0.222 ± 9.816
SecondaryChange From Baseline in Insulin Dose Responsiveness for Carbon Monoxide Diffusing Capacity (DLco) Measured 10 and 60 Minutes After the First Daily Dose of Insulin

Carbon Monoxide Diffusing Capacity (DLco) dose responsivness 10 and 60 minutes after insulin. DLco dose-responsiveness to insulin was defined as the difference between the DLco value following a dose of insulin and DLco value before a dose of insulin, operationally defined as the post-dose DLco value minus pre-dose DLco value.

Time frame:
Baseline, Week 9, Week 51
Reported as:
Mean · ml/min/mmHg
Change From Baseline in Insulin Dose Responsiveness for Carbon Monoxide Diffusing Capacity (DLco) Measured 10 and 60 Minutes After the First Daily Dose of Insulin
ml/min/mmHgInhaled InsulinSubcutaneous Insulin
Baseline: 10 minutes (n=122, 129)-0.163 ± 0.992-0.184 ± 0.985
Week 9: 10 minutes (n=102, 104)-0.241 ± 1.390-0.131 ± 1.006
Week 51: 10 minutes (n=95, 109)-0.139 ± 0.893-0.171 ± 0.820
Baseline: 60 minutes (n=135, 133)-0.446 ± 1.115-0.451 ± 1.258
Week 9: 60 minutes (n=104, 108)-0.338 ± 1.416-0.159 ± 1.126
Week 51: 60 minutes (n=101, 110)-0.216 ± 1.458-0.383 ± 1.030
SecondaryMethacholine Challenge

Methacholine Challange: performed on a subset of subjects using the 5-breath dosimeter method. Subjects were challenged with ascending doses of nebulized methacholine; dosing schedule: 0.03, 0.06, 0.12, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16.0, 32.0 milligrams per milliliter (mg/ml) administered in 5-minute intervals. Forced expiratory volume in 1 second (FEV1) was measured 1-3 minutes after each inhalation of methacholine solution. Testing continued until highest FEV1 decreased by ≥20% from the challenge (post-diluent) reference, or until completion all doses.

Time frame:
1 to 2 days following Weeks -3 and -1 visits, and at Week 11, Week 50, and Week 52 (+5)
Reported as:
Mean · liters

No measurements were reported for this outcome.

SecondaryMean Weekly Morning and Evening Peak Expiratory Flow Rate (PEFR) and Forced Expiratory Volume in 1 Second (FEV1)

Subjects measured peak expiratory flow rate (PEFR) and forced expiratory volume in 1 second (FEV1) twice daily and entered the results in an electronic diary. Daily data were used to calculate the mean PEFR and FEV1 for each week (observed weekly mean and change from baseline in weekly mean). For each subject, the mean weekly morning (and evening) PEFR and FEV1 was defined as the sum of the daily morning (and evening) PEFR (and FEV1) measurements during the week divided by the number of non-missing PEFR (and FEV1) measurements during the week.

Time frame:
Week -3 through Week 52
Reported as:
Mean · liters

No measurements were reported for this outcome.

SecondaryMean Weekly Number of Puffs of Albuterol Used (Rescue Medication)

All subjects used an electronic symptom diary to record their daily use of short-acting bronchodilators. Subjects recorded the sum of their short-acting bronchodilator use (puffs of albuterol) daily, immediately upon arising, and again in the evening or before bed.

Time frame:
Daily: Baseline to end of study
Reported as:
Mean · number of puffs

No measurements were reported for this outcome.

SecondaryNumber of Subjects With Step-up and Step-down Changes in Classification of Asthma Severity by Medication Usage

All asthma medication changes during the study were classified as step-up or step-down according to treatment guidelines. Step 1: Intermittant Asthma; Step 2: Mild Persistent Asthma; Step 3: Moderate Persistent Asthma; Step 4: Severe Persistent Asthma. The number of subjects in each step classification of asthma severity were provided at each assessment timepoint for each treatment group, with a shift table indicating the number of subjects moving from each step classification at each timepoint.

Time frame:
Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52, Week 54, Week 58
Reported as:
Number · subjects

No measurements were reported for this outcome.

SecondaryStep Classification of Asthma Severity by Medication Usage

Step classification of asthma severity by medication usage. Subjects were classified at each visit according to the medication used on the day of the particular time-point; Step 1: intermittent asthma, Step 2: mild persistent asthma, Step 3: moderate persistent asthma, Step 4: severe persistent asthma. The number (%) of subjects in each step classification were provided at each assessment timepoint with a shift table indicating the number (%) of subjects moving from each step classification at each time-point.

Time frame:
Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52, Week 54, Week 58
Reported as:
Number · subjects

No measurements were reported for this outcome.

SecondaryMean Weekly Asthma Symptom Scores

Mean weekly asthma symptom scores: subjects recorded their asthma symptom scores in an electronic symptom diary twice daily throughout the study, immediately upon awakening (5-10 AM) and in the evening or at bedtime (7-12 PM). Questions included extent of albuterol use, symptoms of wheezing, coughing, activity limitations and sleep; scale 0 (none/fine) to 3 (severe/ continuous/bad night).

Time frame:
Baseline through end of study
Reported as:
Mean · scores on scale

No measurements were reported for this outcome.

SecondaryIncidence of Non-severe Asthma Exacerbations

Non-severe asthma exacerbation = one of the following: any home monitored morning (4:45 am - 10:15 am) forced expiratory volume in 1 second (FEV1) \<80% of the morning baseline for 2 or more consecutive days; or home monitored FEV1 \<60% of Baseline at any time. Percent of Baseline = 100\*(daily FEV1)/Baseline weekly FEV1. Subject-months=elapsed number of months a subject was in the study in each time interval. Crude event rate = total events divided by subject-months.

Time frame:
0 to 1 week to > 12 months
Reported as:
Number · events/subject-months
Incidence of Non-severe Asthma Exacerbations
events/subject-monthsInhaled InsulinSubcutaneous Insulin
0 to 1 Week (n=141, 139)0.430.41
>1 to 2 Weeks (n=141, 139)0.280.38
>2 to 3 Weeks (n=141, 139)0.220.31
>3 to 4 Weeks (n=141, 139)0.370.41
>4 to 6 Weeks (n=141, 139)0.520.36
>6 to 9 Weeks (n=138, 139)0.530.51
>9 to 12 Weeks (n=134, 138)0.350.46
>3 Months (n=133, 137)0.400.40
>6 to 9 Months (n=121, 133)0.300.49
>9 to 12 Months (n=114, 131)0.270.43
>12 Months (n=67, 81)0.340.21
Overall (n=141, 139)0.350.43
SecondaryIncidence of Severe Asthma Exacerbations

Severe asthma exacerbation was defined as one of the following: subject received oral (systemic) corticosteriods for the treatment of asthma; or subject had an unscheduled visit to a physician, emergency room, or hospital for the treatment of asthma. Subject-months=elapsed number of months a subject was in the study in each time interval. Crude event rate = total events divided by subject-months \* 100.

Time frame:
0 to 1 Week to > 12 Months
Reported as:
Number · events/subject months*100
Incidence of Severe Asthma Exacerbations
events/subject months*100Inhaled InsulinSubcutaneous Insulin
0 to 1 Week (n=141, 139)0.000.00
>1 to 2 Weeks (n=141, 139)0.003.13
>2 to 3 Weeks (n=141, 139)0.009.39
>3 to 4 Weeks (n=141, 139)3.080.00
>4 to 6 Weeks (n=141, 139)4.631.56
>6 to 9 Weeks (n=138, 139)1.060.00
>9 to 12 Weeks (n=134, 138)1.090.00
>3 Months (n=133, 137)1.202.27
>6 to 9 Months (n=121, 133)1.431.01
>9 to 12 Months (n=114, 131)1.531.33
>12 Months (n=67, 81)3.390.00
Overall (n=141, 139)1.461.47
SecondaryNumber of Systemic Corticosteroid Rescues

Number of subjects who used a systemic corticosteroid at any time during the study, and the total number of systemic corticosteroid rescues. New rescue event = \>=2 consecutive days between the end of one event and the start of another event.

Time frame:
Baseline through Week 52
Reported as:
Number · systemic corticosteriod rescues
Number of Systemic Corticosteroid Rescues
systemic corticosteriod rescuesInhaled InsulinSubcutaneous Insulin
Number of Systemic Corticosteroid Rescues1416
PrimaryAnnualized Rate of Change for Hemoglobin-adjusted Carbon Monoxide Diffusion Capacity (DLco)

Annualized rates of change (slope throughout time from baseline to end of study\[visit\]) for hemoglobin-adjusted carbon monoxide diffusion capacity (DLco)in milliliters per minute/millimeters of mercury/year (ml/min/mmHg/yr) measured 30 minutes following the administration of albuterol.

Time frame:
Weeks -3, -2, -1, 1, 2, 3, 4, 6, 12, 18, 26, 39, and 52
Reported as:
Mean · ml/min/mmHg/yr
Annualized Rate of Change for Hemoglobin-adjusted Carbon Monoxide Diffusion Capacity (DLco)
ml/min/mmHg/yrInhaled InsulinSubcutaneous Insulin
Annualized Rate of Change for Hemoglobin-adjusted Carbon Monoxide Diffusion Capacity (DLco)-0.776 ± 0.152-0.273 ± 0.153
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · Longitudinal data analysis model · Mean difference (final values): -0.503 · 90% CI -0.858 to -0.148Primary analysis model includes terms of Treatment, Time, Baseline Pulmonary Function Test (PFT), Center, Age, Sex, Baseline Height, Type of Diabetes, and Controller Medications Use on day of randomization.
SecondaryAsthma Control as Measured by the Asthma Control Questionnaire©

Asthma Control Questionnaire©: 6 self-administered questions that assess asthma control over the past week covering nocturnal waking, morning symptoms, activity limitations, shortness of breath, wheezing, and short-acting bronchodilator use; 7-point ordinal rating scale from 0 (good control) to 6 (poor control). A seventh question was completed by a health professional on forced expiratory volume in 1 second (FEV1) % predicted using a one-week recall period; scale: 0 (\>95% predicted) to 6 (\<50% predicted). Overall score = mean of questions 1 - 7.

Time frame:
Baseline, Weeks 4, 12, 26, 39, 52
Reported as:
Mean · scores on scale
Asthma Control as Measured by the Asthma Control Questionnaire©
scores on scaleInhaled InsulinSubcutaneous Insulin
Baseline: Subject Evaluation (n=138, 138)1.04 ± 0.781.21 ± 0.91
Baseline: Clinical Evaluation (n=138, 138)2.50 ± 1.502.54 ± 1.70
Baseline: Overall Evaluation (n=138, 138)1.25 ± 0.741.40 ± 0.86
Week 4: Subject Evaluation (n=123, 121)1.08 ± 0.811.15 ± 0.89
Week 4: Clinical Evaluation (n=123, 121)2.68 ± 1.522.65 ± 1.61
Week 4: Overall Evaluation (n=123, 121)1.31 ± 0.781.36 ± 0.81
Week 12: Subject Evaluation (n=129, 134)1.04 ± 0.831.17 ± 0.91
Week 12: Clinical Evaluation (n=129, 134)2.55 ± 1.502.61 ± 1.48
Week 12: Overall Evaluation (n=129, 134)1.25 ± 0.771.37 ± 0.83
Week 26: Subject Evaluation (n=121, 131)1.06 ± 0.801.07 ± 0.91
Week 26: Clinical Evaluation (n=121, 131)2.48 ± 1.432.61 ± 1.57
Week 26: Overall Evaluation (n=121, 131)1.27 ± 0.741.29 ± 0.85
Week 39: Subject Evaluation (n=110, 125)0.94 ± 0.761.00 ± 0.85
Week 39: Clinical Evaluation (n=110, 125)2.54 ± 1.432.63 ± 1.52
Week 39: Overall Evaluation (n=110, 125)1.17 ± 0.711.23 ± 0.81
Week 52: Subject Evaluation (n=107, 120)1.08 ± 1.070.98 ± 0.84
Week 52: Clinical Evaluation (n=107, 120)2.77 ± 1.542.64 ± 1.56
Week 52: Overall Evaluation (n=107, 120)1.32 ± 0.991.21 ± 0.80
Week 4: Subject Eval: Change from BL (n=122, 120)0.02 ± 0.59-0.07 ± 0.59
Week 4: Clinical Eval: Change from BL (n=122, 120)0.17 ± 0.850.14 ± 0.85
Week 4: Overall Eval: Change from BL (n=122, 120)0.04 ± 0.55-0.04 ± 0.53
Week 12: Subject Eval: Change from BL (n=129, 134)-0.02 ± 0.66-0.04 ± 0.72
Week 12 Clinical Eval: Change from BL (n=129, 134)0.12 ± 0.940.09 ± 0.91
Week 12: Overall Eval: Change from BL (n=129, 134)0.00 ± 0.59-0.02 ± 0.62
Week 26: Subject Eval: Change from BL (n=121, 130)0.05 ± 0.77-0.12 ± 0.82
Week 26 Clinical Eval: Change from BL (n=121, 130)0.09 ± 0.780.09 ± 1.00
Week 26: Overall Eval: Change from BL (n=121, 130)0.05 ± 0.68-0.09 ± 0.73
Week 39: Subject Eval: Change from BL (n=110, 124)-0.09 ± 0.65-0.19 ± 0.77
Week 39 Clinical Eval: Change from BL (n=110, 124)0.14 ± 1.050.11 ± 0.94
Week 39: Overall Eval: Change from BL (n=110, 124)-0.06 ± 0.58-0.15 ± 0.68
Week 52: Subject Eval: Change from BL (n=106, 119)0.06 ± 0.88-0.19 ± 0.86
Week 52 Clinical Eval: Change from BL (n=106, 119)0.38 ± 0.870.10 ± 1.20
Week 52: Overall Eval: Change from BL (n=106, 119)0.11 ± 0.77-0.15 ± 0.77
SecondaryBaseline Dyspnea Index (BDI)

Total score = the sum of the numeric grades from the three dyspnea index questions. Functional Impairment rating scale: Grade 4 (no impairment) to Grade 0 (very severe impairment); Magnitude of Task rating scale: Grade 4 (extraordinary) to Grade 0 (no task); and Magnitude of Effort rating scale: Grade 4 (extraordinary) to grade 0 (no effort).

Time frame:
run-in period
Reported as:
Mean · scores on scale
Baseline Dyspnea Index (BDI)
scores on scaleInhaled InsulinSubcutaneous Insulin
Functional Impairment3.37 ± 0.803.36 ± 0.87
Magnitude of Task2.29 ± 1.192.29 ± 1.25
Magnitude of Effort2.49 ± 1.392.34 ± 1.49
Total Score8.15 ± 2.987.97 ± 2.99
SecondaryTransition Dyspnea Index (TDI): Change in Total Score

Transition Dyspnea Index total score = sum of the numeric grades from the three dyspnea index questions: Change in Functional Impairment, Change in Magnitude of Task, and Change in Magnitude of Effort. Rating scale: -3 (major deterioration), -2 (moderate deterioration), -1 (minor deterioration, 0 (no change), +1 (minor improvement), +2 (moderate improvement), +3 (major improvement).

Time frame:
Week 4, Week 12, Week 26, Week 39, Week 52
Reported as:
Mean · scores on scale
Transition Dyspnea Index (TDI): Change in Total Score
scores on scaleInhaled InsulinSubcutaneous Insulin
Week 4 (n=121, 122)0.36 ± 1.930.50 ± 1.92
Week 12 (n=131, 135)0.51 ± 1.760.47 ± 1.68
Week 26 (n=124, 131)0.14 ± 1.750.13 ± 1.55
Week 39 (n=112, 127)0.26 ± 1.560.29 ± 1.61
Week 52 (n=105, 121)0.13 ± 1.650.67 ± 2.01
SecondaryGlycosylated Hemoglobin (HbA1c)

Glycosylated Hemoglobin (HbA1c): observed mean values at Baseline and each observation, and change from Baseline. Change from Baseline = mean HbA1c at observation minus mean HbA1c at Baseline.

Time frame:
Baseline, Week 6, Week 12, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Reported as:
Mean · percent
Glycosylated Hemoglobin (HbA1c)
percentInhaled InsulinSubcutaneous Insulin
Baseline (n=135, 135)7.62 ± 1.127.43 ± 1.08
Week 6: Observed Value (n=127, 126)7.22 ± 1.006.97 ± 0.90
Week 6: Change from Baseline (n=127, 126)-0.38 ± 0.65-0.43 ± 0.49
Week 12: Observed Value (n=122, 127)7.28 ± 1.126.98 ± 0.97
Week 12: Change from Baseline (n=122, 127)-0.32 ± 0.98-0.48 ± 0.69
Week 26: Observed Value (n=118, 120)7.38 ± 1.247.19 ± 1.18
Week 26: Change from Baseline (n=118, 120)-0.12 ± 1.07-0.25 ± 0.93
Week 39: Observed Value (n=108, 123)7.44 ± 1.317.20 ± 1.16
Week 39: Change from Baseline (n=108, 123)-0.08 ± 1.10-0.21 ± 0.91
Week 52: Observed Value (n=101, 118)7.51 ± 1.357.35 ± 1.28
Week 52: Change from Baseline (n=101, 118)0.00 ± 1.05-0.05 ± 1.01
Week 52 (LOCF): Observed Value (n=135, 135)7.58 ± 1.357.40 ± 1.36
Week 52 (LOCF): Change from Baseline (n=135, 135)-0.04 ± 1.07-0.03 ± 1.04
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): 0.11 · 90% CI -0.06 to 0.28
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): 0.21 · 90% CI 0.04 to 0.38
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): 0.17 · 90% CI -0.01 to 0.34
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): 0.14 · 90% CI -0.03 to 0.32
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): 0.06 · 90% CI -0.12 to 0.24
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): 0.01 · 90% CI -0.19 to 0.22
SecondaryFasting Plasma Glucose

Fasting plasma glucose (milligrams per deciliter \[mg/dL\]) at Baseline, and change from Baseline. Change from baseline: mean of value of fasting plasma glucose in mg/dL at observation minus baseline value.

Time frame:
Baseline, Week 6, Week 12, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Reported as:
Mean · mg/dL
Fasting Plasma Glucose
mg/dLInhaled InsulinSubcutaneous Insulin
Baseline (n=112, 123)149.22 ± 49.92149.03 ± 58.33
Week 6: Observed Value (n=103, 112)143.02 ± 68.92136.54 ± 57.98
Week 6: Change from Baseline (n=103, 112)-3.34 ± 68.47-15.19 ± 67.16
Week 12: Observed Value (n=106, 113)136.32 ± 63.00144.47 ± 61.22
Week 12: Change from Baseline (n=106, 113)-12.16 ± 65.62-5.40 ± 67.71
Week 26: Observed Value (n=102, 114)139.05 ± 64.63143.54 ± 52.09
Week 26: Change from Baseline (n=102, 114)-11.86 ± 76.07-4.63 ± 65.10
Week 39: Observed Value (n=102, 115)143.64 ± 63.89142.91 ± 66.26
Week 39: Change from Baseline (n=102, 115)-5.67 ± 67.65-7.47 ± 65.55
Week 52: Observed Value (n=98, 115)146.32 ± 66.04145.43 ± 59.35
Week 52: Change from Baseline (n=98, 115)-3.86 ± 60.61-2.53 ± 63.23
Week 52 LOCF: Observed Value (n=112, 123)148.28 ± 71.07144.96 ± 58.80
Week 52 LOCF: Change from Baseline (n=112, 123)-0.95 ± 72.53-4.07 ± 62.75
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): 10.615 · 90% CI -2.351 to 23.581Confidence interval for the LS mean of that particular treatment.
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -6.942 · 90% CI -19.79 to 5.909
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -4.622 · 90% CI -17.63 to 8.382
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): 1.828 · 90% CI -11.16 to 14.817
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): 1.149 · 90% CI -12.01 to 14.307
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): 4.247 · 90% CI -8.664 to 17.157
SecondaryBody Weight: Mean Baseline and Change From Baseline

Body weight: mean Baseline and change from Baseline in kilograms (kg). Change from baseline = mean body weight in kilograms (kg) at observation minus baseline value.

Time frame:
Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 11, Week 12, Week 18, Wek 26, Week 39, Week 50, Week 51, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Reported as:
Mean · kilograms
Body Weight: Mean Baseline and Change From Baseline
kilogramsInhaled InsulinSubcutaneous Insulin
Baseline (n=113, 124)87.41 ± 21.0487.13 ± 17.58
Week 1: Change from Baseline (n=102, 113)-0.02 ± 1.451.00 ± 7.63
Week 2: Change from Baseline (n=104, 105)0.12 ± 1.310.57 ± 1.50
Week 3: Change from Baseline (n=103, 113)0.18 ± 1.640.34 ± 1.55
Week 4: Change from Baseline (n=101, 119)0.31 ± 1.740.44 ± 1.70
Week 6: Change from Baseline (n=106, 122)0.13 ± 1.930.68 ± 1.88
Week 9: Change from Baseline (n=101, 104)0.14 ± 2.310.91 ± 2.33
Week 11: Change from Baseline (n=14, 17)0.71 ± 1.770.69 ± 2.00
Week 12: Change from Baseline (n=106, 118)0.01 ± 2.960.84 ± 2.83
Week 18: Change from Baseline (n=110, 116)0.35 ± 3.041.27 ± 3.46
Week 26: Change from Baseline (n=111, 121)0.72 ± 3.521.29 ± 3.32
Week 39: Change from Baseline (n=107, 121)0.77 ± 4.331.33 ± 3.70
Week 50: Change from Baseline (n=19, 13)0.04 ± 3.671.98 ± 3.90
Week 51: Change from Baseline (n=49, 60)0.24 ± 3.750.63 ± 4.38
Week 52: Change from Baseline (n=90, 109)1.34 ± 3.981.26 ± 4.08
Week 52 LOCF: Change from Baseline (n=113, 124)1.13 ± 3.951.44 ± 4.13
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -1.080 · 90% CI -1.829 to -0.331
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.475 · 90% CI -1.233 to 0.284
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.185 · 90% CI -0.931 to 0.562
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.189 · 90% CI -0.929 to 0.550
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.558 · 90% CI -1.294 to 0.178
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.748 · 90% CI -1.517 to 0.022
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -1.053 · 90% CI -2.510 to 0.405
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.891 · 90% CI -1.634 to -0.149
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.980 · 90% CI -1.725 to -0.234
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.663 · 90% CI -1.400 to 0.075
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.537 · 90% CI -1.279 to 0.205
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -1.322 · 90% CI -3.012 to 0.369
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): 0.063 · 90% CI -0.847 to 0.972
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.193 · 90% CI -0.964 to 0.579
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.430 · 90% CI -1.298 to 0.438
SecondaryTotal Daily Long-Acting Insulin Dose (Unadjusted for Body Weight)

Total Daily Long-Acting Insulin Dose Unadjusted for Body Weight: long-acting insulin included Insulin NPH, Ultralente, and Insulin Glargine for both groups. Inhaled Insulin reported in mg. Subcutaneous Insulin reported in units.

Time frame:
Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52
Reported as:
Mean · mg, units
Total Daily Long-Acting Insulin Dose (Unadjusted for Body Weight)
mg, unitsInhaled Insulin (mg)Subcutaneous Insulin (Units)
Baseline (n=105, 121)41.70 ± 24.6145.50 ± 27.54
Week 1 (n=104, 117)41.75 ± 25.7545.46 ± 28.69
Week 2 (n=106, 111)43.48 ± 26.7647.19 ± 28.08
Week 3 (n=104, 117)43.75 ± 27.3247.61 ± 29.06
Week 4 (n=104, 120)44.70 ± 28.0648.54 ± 29.91
Week 6 (n=106, 122)45.89 ± 29.3148.59 ± 30.68
Week 9 (n=104, 109)46.01 ± 30.5747.68 ± 29.16
Week 12 (n=110, 122)46.05 ± 30.8249.04 ± 30.99
Week 18 (n=110, 120)47.15 ± 32.3449.94 ± 30.95
Week 26 (n=111, 122)47.65 ± 33.8749.98 ± 31.32
Week 39 (n=107, 121)48.97 ± 33.2850.32 ± 31.58
Week 52 (n=101, 119)50.17 ± 34.1750.07 ± 31.62
SecondaryTotal Daily Long-Acting Insulin Dose Adjusted for Body Weight

Total daily dose of long-acting insulin adjusted for body weight (units per kilogram \[kg\]). Long-acting insulin included Insulin NPH, Ultralente, and Insulin Glargine for both groups. Inhaled Insulin reported in mg/kg. Subcutaneous Insulin reported in units/kg.

Time frame:
Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52
Reported as:
Mean · mg/kg, units/kg
Total Daily Long-Acting Insulin Dose Adjusted for Body Weight
mg/kg, units/kgInhaled Insulin (mg/kg)Subcutaneous Insulin (Units/kg)
Baseline (n=105, 121)0.47 ± 0.250.52 ± 0.30
Week 1 (n=100, 112)0.47 ± 0.270.53 ± 0.31
Week 2 (n=103, 104)0.49 ± 0.290.52 ± 0.28
Week 3 (n=101, 113)0.49 ± 0.290.54 ± 0.31
Week 4 (n=99, 118)0.49 ± 0.270.54 ± 0.31
Week 6 (n=104, 121)0.52 ± 0.310.55 ± 0.32
Week 9 (n=99, 103)0.51 ± 0.310.54 ± 0.32
Week 12 (n=104, 117)0.52 ± 0.320.55 ± 0.32
Week 18 (n=108, 115)0.53 ± 0.330.55 ± 0.32
Week 26 (n=109, 120)0.52 ± 0.330.55 ± 0.32
Week 39 (n=105, 120)0.54 ± 0.370.56 ± 0.32
Week 52 (n=88, 108)0.53 ± 0.360.55 ± 0.31
SecondaryTotal Daily Short-Acting Insulin Dose (Unadjusted for Body Weight)

Average Total Daily Insulin Dose: short-acting insulin (milligrams \[mg\]). Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.

Time frame:
Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52
Reported as:
Mean · mg, units
Total Daily Short-Acting Insulin Dose (Unadjusted for Body Weight)
mg, unitsInhaled Insulin (mg)Subcutaneous Insulin (Units)
Baseline (n=109, 122)30.56 ± 22.6930.74 ± 19.50
Week 1 (n=106, 118)11.03 ± 5.5129.52 ± 19.95
Week 2 (n=108, 111)12.13 ± 6.0331.24 ± 21.69
Week 3 (n=106, 116)12.96 ± 6.6830.58 ± 20.70
Week 4 (n=106, 120)13.44 ± 6.8231.87 ± 22.23
Week 6 (n=108, 122)14.04 ± 7.0631.81 ± 21.94
Week 9 (n=106, 110)14.03 ± 7.7631.55 ± 23.93
Week 12 (n=112, 122)14.42 ± 8.1132.71 ± 23.70
Week 18 (n=112, 120)15.11 ± 8.6833.49 ± 23.81
Week 26 (n=113, 122)15.95 ± 9.1433.80 ± 24.37
Week 39 (n=109, 121)16.17 ± 10.2533.12 ± 24.62
Week 52 (n= 103, 119)17.20 ± 10.9533.04 ± 26.09
SecondaryTotal Daily Short-Acting Insulin Dose Adjusted for Body Weight

Total Daily Short-Acting Insulin Dose adjusted for body weight (units divided by kg). Short-acting insulin (mg) for the Inhaled Insulin group was Inhaled Insulin. Short-acting insulin (unit) for the Subcutaneous Insulin group included Insulin Lispro, Insulin Aspart, and Regular Insulin.

Time frame:
Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12, Week 18, Week 26, Week 39, Week 52
Reported as:
Mean · mg/kg, units/kg
Total Daily Short-Acting Insulin Dose Adjusted for Body Weight
mg/kg, units/kgInhaled Insulin (mg/kg)Subcutaneous Insulin (Units/kg)
Baseline (n=109, 122)0.35 ± 0.250.36 ± 0.22
Week 1 (n=102, 113)0.12 ± 0.060.34 ± 0.23
Week 2 (n=104, 104)0.14 ± 0.070.36 ± 0.25
Week 3 (n=103, 112)0.15 ± 0.070.35 ± 0.23
Week 4 (n=101, 118)0.15 ± 0.070.37 ± 0.26
Week 6 (n=106, 121)0.16 ± 0.080.36 ± 0.24
Week 9 (n=101, 104)0.16 ± 0.090.36 ± 0.26
Week 12 (n=106, 117)0.16 ± 0.080.38 ± 0.26
Week 18 (n=110, 116)0.18 ± 0.100.37 ± 0.25
Week 26 (n=111, 121)0.19 ± 0.110.38 ± 0.27
Week 39 (n=107, 120)0.19 ± 0.120.38 ± 0.27
Week 52 (n=90, 108)0.19 ± 0.120.36 ± 0.29
SecondaryLipids: Median Change From Baseline to Last Observation

Lipids: median changes (milligrams per deciliter \[mg/dL\]) from Baseline median to last observation in cholesterol (random), triglycerides (random), high density lipoprotein (HDL) cholesterol and low density lipoprotein (LDL) cholesterol. Normalized data was used in the computations. Last observation = last observation while on study drug or during the lag. Measures of dispersion for median changes in lipids were not determined.

Time frame:
Baseline to Last Observation
Reported as:
Number · mg/dL
Lipids: Median Change From Baseline to Last Observation
mg/dLInhaled InsulinSubcutaneous Insulin
Cholesterol (random) (n=110, 121)-0.5 ± -0.50 ± 0
Triglycerides (random) (n=105, 121)9 ± 9-8 ± -8
HDL Cholesterol (n=110, 121)-3 ± -31 ± 1
LDL Cholesterol (n=97, 110)0 ± 00 ± 0
SecondaryHypoglycemic Event Rates

A Hypoglycemic event was identified by characteristic symptoms of hypoglycemia with no blood glucose check with prompt resolution with food intake, subcutaneous glucagon, or intravenouus glucose; characteristic symptoms with blood glucose of 59 milligrams per deciliter (mg/dL) (3.2 mmol/L) or less with blood glucose check; or any glucose measurement of 49 mg/dL (2.7 mmol/L) or less, with or without symptoms. Crude event rate = total events divided by subject months. Subject months = elapsed number of months a subject was in the study in each time interval.

Time frame:
0 to 1 month to 11 to 12 months, and Overall
Reported as:
Number · events / subject-months
Hypoglycemic Event Rates
events / subject-monthsInhaled InsulinSubcutaneous Insulin
0 to 1 month (n=135, 135)2.992.48
> 1 to 2 months (n=135, 135)2.522.34
> 2 to 3 months (n=131, 134)2.121.84
> 3 to 4 months (n=128, 134)1.841.61
> 4 to 5 months (n=126, 134)1.941.69
> 5 to 6 months (n=121, 131)1.511.84
> 6 to 7 months (n=119, 131)1.501.67
> 7 to 8 months (n=115, 129)1.451.26
> 8 to 9 months (n=111, 129)1.621.26
> 9 to 10 months (n=110, 129)1.261.55
> 10 to 11 months (n=109, 125)1.121.37
> 11 to 12 months (n=104, 123)1.181.23
Overall (n=135, 135)1.791.68
SecondarySevere Hypoglycemic Event Rates

Severe hypoglycemic event = all 3 of the following criteria were met: subject unable to treat self, exhbited at least 1 neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, suspected seizure, loss of consciousness); blood glucose measurement was ≤ 49 mg/dL, or not measured but clinical manifestations reversed by oral carbohydrates, subcutaneous glucagon, or i.v. glucose. Crude event rate = number of events divided by 100 subject-months. Subject months = elapsed number of months subject was in study in each time interval.

Time frame:
0 to 1 month to 11 to 12 months, and Overall
Reported as:
Number · Number of events/100 subject-months.
Severe Hypoglycemic Event Rates
Number of events/100 subject-months.Inhaled InsulinSubcutaneous Insulin
0 to 1 month (n=135, 135)2.911.48
> 1 to 2 months (n=135, 135)5.221.49
> 2 to 3 months (n=131, 134)4.642.99
> 3 to 4 months (n=128, 134)0.782.24
> 4 to 5 months (n=126, 134)4.051.51
> 5 to 6 months (n=121, 131)3.332.29
> 6 to 7 months (n=119, 131)0.000.77
> 7 to 8 months (n=115, 129)0.892.33
> 8 to 9 months (n=111, 129)5.421.55
> 9 to 10 months (n=110, 129)0.913.18
> 10 to 11 months (n=109, 125)1.882.41
> 11 to 12 months (n=104, 123)3.953.10
Overall (n=135, 135)2.892.13
PrimaryChange From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second (FEV1)

Change from Baseline at each visit in post-bronchodilator forced expiratory volume in one second (FEV1). FEV1 was measured in liters (L) 30 minutes following the administration of albuterol. Change from baseline: mean FEV1 (L) at observation minus baseline value.

Time frame:
Baseline through Week 52 Last Observation Carried Forward (LOCF)
Reported as:
Mean · liters
Change From Baseline in Post-Bronchodilator Forced Expiratory Volume in One Second (FEV1)
litersInhaled InsulinSubcutaneous Insulin
Baseline (n=141, 139)2.559 ± 0.7712.524 ± 0.742
Week 1 (n=123, 125)-0.066 ± 0.150-0.027 ± 0.126
Week 2 (n=126, 115)-0.056 ± 0.150-0.031 ± 0.128
Week 3 (n=131, 119)-0.077 ± 0.185-0.030 ± 0.130
Week 4 (n=121, 129)-0.074 ± 0.161-0.022 ± 0.155
Week 6 (n=130, 135)-0.070 ± 0.248-0.025 ± 0.146
Week 12 (n=125, 129)-0.053 ± 0.212-0.031 ± 0.182
Week 18 (n=124, 125)-0.066 ± 0.226-0.040 ± 0.165
Week 26 (n=120, 128)-0.056 ± 0.175-0.038 ± 0.184
Week 39 (n=107, 124)-0.088 ± 0.191-0.039 ± 0.194
Week 52 (n=106, 112)-0.131 ± 0.259-0.059 ± 0.234
Week 52 LOCF (n=141, 139)-0.113 ± 0.261-0.062 ± 0.225
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.039 · 90% CI -0.079 to -0.000
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.029 · 90% CI -0.068 to 0.010
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.045 · 90% CI -0.084 to -0.006
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.046 · 90% CI -0.085 to -0.007
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.046 · 90% CI -0.085 to -0.007
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.023 · 90% CI -0.063 to 0.017
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.021 · 90% CI -0.062 to 0.020
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.014 · 90% CI -0.055 to 0.027
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.042 · 90% CI -0.085 to 0.000
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.065 · 90% CI -0.109 to -0.022
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.050 · 90% CI -0.097 to -0.003
PrimaryChange From Baseline in Post-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco)

Carbon Monoxide Diffusing Capacity (DLco) measured in milliters/minutes/millimeters of mercury (mL/min/mmHg) 30 minutes following the administration of albuterol. Change from Baseline: mean DLco (mL/min/mmHg) at observation minus baseline value.

Time frame:
Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 12, Week 18, Week 26, Week 39, Week 52, Week 52 Last Observation Carried Forward (LOCF)
Reported as:
Mean · mL/min/mmHg
Change From Baseline in Post-Bronchodilator Carbon Monoxide Diffusing Capacity (DLco)
mL/min/mmHgInhaled InsulinSubcutaneous Insulin
Baseline (n=141, 139)23.023 ± 5.91422.883 ± 6.079
Week 1 (n=122, 124)-0.574 ± 1.392-0.333 ± 1.405
Week 2 (n=126, 112)-0.777 ± 1.631-0.481 ± 1.290
Week 3 (n=129, 118)-0.811 ± 1.244-0.506 ± 1.388
Week 4 (n=120, 128)-1.075 ± 1.425-0.576 ± 1.397
Week 6 (n=129, 135)-1.017 ± 1.633-0.602 ± 1.488
Week 12 (n=125, 125)-0.961 ± 1.738-0.477 ± 1.588
Week 18 (n=124, 123)-1.024 ± 1.774-0.549 ± 1.601
Week 26 (n=119, 127)-0.849 ± 1.914-0.477 ± 1.706
Week 39 (n=107, 123)-1.016 ± 1.649-0.395 ± 1.767
Week 52 (n=105, 110)-1.483 ± 1.944-0.798 ± 1.967
Week 52 LOCF (n=141, 139)-1.426 ± 1.856-0.682 ± 1.958
Statistical analysis
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.279 · 90% CI -0.606 to 0.048
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.336 · 90% CI -0.661 to -0.011
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.384 · 90% CI -0.707 to -0.061
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.516 · 90% CI -0.842 to -0.191
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.474 · 90% CI -0.797 to -0.152
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.533 · 90% CI -0.866 to -0.200
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.509 · 90% CI -0.845 to -0.174
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.412 · 90% CI -0.749 to -0.076
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.707 · 90% CI -1.056 to -0.358
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.680 · 90% CI -1.040 to -0.320
  • Inhaled Insulin vs Subcutaneous Insulin · Mixed Models Analysis · Mean difference (final values): -0.765 · 90% CI -1.116 to -0.415

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inhaled Insulin—21/146 (14.4%)140/146 (95.9%)
Subcutaneous Insulin—13/141 (9.2%)136/141 (96.5%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventInhaled InsulinSubcutaneous Insulin
HypoglycaemiaMetabolism and nutrition disorders3/1460/141
AsthmaRespiratory, thoracic and mediastinal disorders3/1462/141
Acute coronary syndromeCardiac disorders0/1462/141
Chest painGeneral disorders2/1461/141
Atrial fibrillationCardiac disorders0/1461/141
Atrial flutterCardiac disorders0/1461/141
Myocardial infarctionCardiac disorders0/1461/141
Abdominal wall abscessInfections and infestations0/1461/141
PneumoniaInfections and infestations0/1461/141
HyperglycaemiaMetabolism and nutrition disorders0/1461/141
Most frequent other events
Showing 10 of 32
Most frequent other events
EventInhaled InsulinSubcutaneous Insulin
HypoglycaemiaMetabolism and nutrition disorders109/146120/141
AsthmaRespiratory, thoracic and mediastinal disorders53/14663/141
Upper respiratory tract infectionInfections and infestations44/14639/141
NasopharyngitisInfections and infestations29/14626/141
CoughRespiratory, thoracic and mediastinal disorders29/14611/141
InfluenzaInfections and infestations20/14625/141
BronchitisInfections and infestations24/14618/141
SinusitisInfections and infestations14/14621/141
Urinary tract infectionInfections and infestations18/14620/141
TremorNervous system disorders8/14617/141

Baseline characteristics

Age, Customized
Age, Customized(participants)Inhaled InsulinSubcutaneous InsulinTotal
18-25 years12820
26-35 years181331
36-45 years232548
46-55 years334174
56-65 years403777
66-75 years201737
Sex: Female, Male
Sex: Female, Male(Participants)Inhaled InsulinSubcutaneous InsulinTotal
Female9791188
Male495099
08

Study locations

102 sites
  • Pfizer Investigational Site
    Glendale, Arizona 85306, United States
  • Pfizer Investigational Site
    Peoria, Arizona 85381, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85004, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85006, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85016, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85715, United States
  • Pfizer Investigational Site
    Jonesboro, Arkansas 72401, United States
  • Pfizer Investigational Site
    Searcy, Arkansas 72143, United States
  • Pfizer Investigational Site
    Berkeley, California 94705, United States
  • Pfizer Investigational Site
    Beverly Hills, California 90211, United States
  • Pfizer Investigational Site
    Fresno, California 93720, United States
  • Pfizer Investigational Site
    Greenbrae, California 94904, United States
  • Pfizer Investigational Site
    Huntington Beach, California 92648, United States
  • Pfizer Investigational Site
    Los Angeles, California 90073, United States
  • Pfizer Investigational Site
    Riverside, California 92506, United States
  • Pfizer Investigational Site
    San Diego, California 92114, United States
  • Pfizer Investigational Site
    San Diego, California 92116, United States
  • Pfizer Investigational Site
    Tustin, California 92780, United States
  • Pfizer Investigational Site
    Boulder, Colorado 80304, United States
  • Pfizer Investigational Site
    Denver, Colorado 80206, United States
  • Pfizer Investigational Site
    Denver, Colorado 80209, United States
  • Pfizer Investigational Site
    Denver, Colorado 80220, United States
  • Pfizer Investigational Site
    Waterbury, Connecticut 06708, United States
  • Pfizer Investigational Site
    Newark, Delaware 19713, United States
  • Pfizer Investigational Site
    Chiefland, Florida 32626, United States
  • Pfizer Investigational Site
    Clearwater, Florida 33756, United States
  • Pfizer Investigational Site
    Clearwater, Florida 33765, United States
  • Pfizer Investigational Site
    Melbourne, Florida 32901, United States
  • Pfizer Investigational Site
    Miami, Florida 33144, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida 33401, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida 33404, United States
  • Pfizer Investigational Site
    Augusta, Georgia 30909, United States
  • Pfizer Investigational Site
    Honolulu, Hawaii 96813, United States
  • Pfizer Investigational Site
    Honululu, Hawaii 96814, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60611, United States
  • Pfizer Investigational Site
    Normal, Illinois 61761, United States
  • Pfizer Investigational Site
    Evansville, Indiana 47713, United States
  • Pfizer Investigational Site
    Indianapolis, Indiana 46250, United States
  • Pfizer Investigational Site
    Des Moines, Iowa 50314, United States
  • Pfizer Investigational Site
    Dubuque, Iowa 52001, United States
  • Pfizer Investigational Site
    Dubuque, Iowa 52002, United States
  • Pfizer Investigational Site
    Wichita, Kansas 67203, United States
  • Pfizer Investigational Site
    Bossier City, Louisiana 71111, United States
  • Pfizer Investigational Site
    North Dartmouth, Massachusetts 02747, United States
  • Pfizer Investigational Site
    Springfield, Massachusetts 01103, United States
  • Pfizer Investigational Site
    Springfield, Massachusetts 01107, United States
  • Pfizer Investigational Site
    Waltham, Massachusetts 02453, United States
  • Pfizer Investigational Site
    Brooklyn Center, Minnesota 55430, United States
  • Pfizer Investigational Site
    St. Louis, Missouri 63141, United States
  • Pfizer Investigational Site
    Butte, Montana 59701, United States
  • Pfizer Investigational Site
    Henderson, Nevada 89015, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89103, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89128, United States
  • Pfizer Investigational Site
    North Las Vegas, Nevada 89032, United States
  • Pfizer Investigational Site
    Albuquerque, New Mexico 87131-5666, United States
  • Pfizer Investigational Site
    Buffalo, New York 14209, United States
  • Pfizer Investigational Site
    New York, New York 10029, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45219, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45231, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45242, United States
  • Pfizer Investigational Site
    Dayton, Ohio 45402, United States
  • Pfizer Investigational Site
    Toledo, Ohio 43606, United States
  • Pfizer Investigational Site
    Toledo, Ohio 43608, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • Pfizer Investigational Site
    Medford, Oregon 97504, United States
  • Pfizer Investigational Site
    Portland, Oregon 97210, United States
  • Pfizer Investigational Site
    Portland, Oregon 97219, United States
  • Pfizer Investigational Site
    Lansdale, Pennsylvania 19446, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15243, United States
  • Pfizer Investigational Site
    Spartanburg, South Carolina 29303, United States
  • Pfizer Investigational Site
    Spartanburg, South Carolina 29307, United States
  • Pfizer Investigational Site
    Bartlett, Tennessee 38133, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38119, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37203, United States
  • Pfizer Investigational Site
    Beaumont, Texas 77701, United States
  • Pfizer Investigational Site
    Dallas, Texas 75231, United States
  • Pfizer Investigational Site
    Houstan, Texas 77079, United States
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
  • Pfizer Investigational Site
    Houston, Texas 77043, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78237, United States
  • Pfizer Investigational Site
    Norfolk, Virginia 23502, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23229, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23235, United States
  • Pfizer Investigational Site
    Spokane, Washington 99202, United States
  • Pfizer Investigational Site
    Spokane, Washington 99204, United States
  • Pfizer Investigational Site
    Porto Alegre, RS 90035-170, Brazil
  • Pfizer Investigational Site
    SP, Sao Paulo 04231-030, Brazil
  • Pfizer Investigational Site
    Campinas, SP 13083-900, Brazil
  • Pfizer Investigational Site
    Sao Paulo, SP 01244-030, Brazil
  • Pfizer Investigational Site
    Edmonton, Alberta T5J 3N4, Canada
  • Pfizer Investigational Site
    Red Deer, Alberta T4N 6V7, Canada
  • Pfizer Investigational Site
    Victoria, British Columbia V8R 1J8, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba R3A 1R9, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba R3E 3P4, Canada
  • Pfizer Investigational Site
    Burlington, Ontario L7M 4Y1, Canada
  • Pfizer Investigational Site
    London, Ontario N6A 4V2, Canada
  • Pfizer Investigational Site
    Laval, Quebec H7T 2P5, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H1T 2M4, Canada
  • Pfizer Investigational Site
    Sherbrooke, Quebec J1H 5N4, Canada

Showing the first 100 of 102 sites across 5 countries. Choose a country and city above to see the rest.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2003, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2010, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2005
First posted
Aug 31, 2005
Start
Jan 2003
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
May 12, 2010
Last update
Jun 2, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00139659
Lead sponsor
Pfizer
First posted
Aug 31, 2005
Start date
Jan 2003
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
May 12, 2010
Last update
Jun 2, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion